Pfizer Total Long-Term Assets 2010-2024 | PFE
Pfizer total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
- Pfizer total long-term assets for the quarter ending September 30, 2024 were $176.254B, a 24.99% increase year-over-year.
- Pfizer total long-term assets for 2023 were $183.168B, a 25.51% increase from 2022.
- Pfizer total long-term assets for 2022 were $145.944B, a 19.84% increase from 2021.
- Pfizer total long-term assets for 2021 were $121.782B, a 2.2% increase from 2020.
Pfizer Annual Total Long-Term Assets
(Millions of US $) |
| 2023 |
$183,168 |
| 2022 |
$145,944 |
| 2021 |
$121,782 |
| 2020 |
$119,162 |
| 2019 |
$134,791 |
| 2018 |
$109,497 |
| 2017 |
$130,655 |
| 2016 |
$132,666 |
| 2015 |
$123,577 |
| 2014 |
$111,972 |
| 2013 |
$115,857 |
| 2012 |
$120,967 |
| 2011 |
$127,185 |
| 2010 |
$134,001 |
| 2009 |
$151,279 |
Pfizer Quarterly Total Long-Term Assets
(Millions of US $) |
| 2024-09-30 |
$176,254 |
| 2024-06-30 |
$178,367 |
| 2024-03-31 |
$178,681 |
| 2023-12-31 |
$183,168 |
| 2023-09-30 |
$141,010 |
| 2023-06-30 |
$146,821 |
| 2023-03-31 |
$145,540 |
| 2022-12-31 |
$145,944 |
| 2022-09-30 |
$124,947 |
| 2022-06-30 |
$127,823 |
| 2022-03-31 |
$129,420 |
| 2021-12-31 |
$121,782 |
| 2021-09-30 |
$121,288 |
| 2021-06-30 |
$121,106 |
| 2021-03-31 |
$119,285 |
| 2020-12-31 |
$119,162 |
| 2020-09-30 |
$131,244 |
| 2020-06-30 |
$131,510 |
| 2020-03-31 |
$131,599 |
| 2019-12-31 |
$134,791 |
| 2019-09-30 |
$136,987 |
| 2019-06-30 |
$109,125 |
| 2019-03-31 |
$110,131 |
| 2018-12-31 |
$109,497 |
| 2018-09-30 |
$126,255 |
| 2018-06-30 |
$127,678 |
| 2018-03-31 |
$129,778 |
| 2017-12-31 |
$130,655 |
| 2017-09-30 |
$131,861 |
| 2017-06-30 |
$132,174 |
| 2017-03-31 |
$132,905 |
| 2016-12-31 |
$132,666 |
| 2016-09-30 |
$139,928 |
| 2016-06-30 |
$126,812 |
| 2016-03-31 |
$121,631 |
| 2015-12-31 |
$123,577 |
| 2015-09-30 |
$125,865 |
| 2015-06-30 |
$109,162 |
| 2015-03-31 |
$111,197 |
| 2014-12-31 |
$111,972 |
| 2014-09-30 |
$114,375 |
| 2014-06-30 |
$114,325 |
| 2014-03-31 |
$114,015 |
| 2013-12-31 |
$115,857 |
| 2013-09-30 |
$116,021 |
| 2013-06-30 |
$117,900 |
| 2013-03-31 |
$122,635 |
| 2012-12-31 |
$120,967 |
| 2012-09-30 |
$125,476 |
| 2012-06-30 |
$124,077 |
| 2012-03-31 |
$130,820 |
| 2011-12-31 |
$127,185 |
| 2011-09-30 |
$133,400 |
| 2011-06-30 |
$135,415 |
| 2011-03-31 |
$136,712 |
| 2010-12-31 |
$134,001 |
| 2010-09-30 |
$137,326 |
| 2010-06-30 |
$139,970 |
| 2010-03-31 |
$145,197 |
| 2009-12-31 |
$151,279 |
| 2009-09-30 |
$67,510 |
| 2009-06-30 |
$67,789 |
| 2009-03-31 |
$68,679 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
